Broadcast Date: 
  • Time: 

Proteolysis-targeting chimeras (PROTACs) are bifunctional molecules that leverage the body’s internal protein disposal system to target and degrade disease-causing proteins. Emerged in 2001, PROTACs offer an attractive therapeutic concept to control target protein levels and have made rapid progress in the drug discovery pipelines. In this GEN webinar our distinguished guest, Dr. Liping Ma, will focus on tackling the DMPK challenges of developing proteolysis-targeting chimeras by providing a research strategy for conducting in vitro ADME and in vivo PK studies, with the goal of helping drug developers quickly advance their projects.


A live Q&A followed the presentation, offering a chance to pose questions to our expert panelist.

Liping Ma
Liping Ma, PhD
Study Director of DMPK,
Laboratory Testing Division
WuXi AppTec

WuXi AppTec logo